CN106470992B - 作为pi3k抑制剂的吡啶并[1,2-a]嘧啶酮类似物 - Google Patents

作为pi3k抑制剂的吡啶并[1,2-a]嘧啶酮类似物 Download PDF

Info

Publication number
CN106470992B
CN106470992B CN201580027396.1A CN201580027396A CN106470992B CN 106470992 B CN106470992 B CN 106470992B CN 201580027396 A CN201580027396 A CN 201580027396A CN 106470992 B CN106470992 B CN 106470992B
Authority
CN
China
Prior art keywords
alkyl
compound
substituted
radical
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580027396.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN106470992A (zh
Inventor
吴成德
于涛
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54934872&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN106470992(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CN201410271282.9A external-priority patent/CN105461711B/zh
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN106470992A publication Critical patent/CN106470992A/zh
Application granted granted Critical
Publication of CN106470992B publication Critical patent/CN106470992B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
CN201580027396.1A 2014-06-17 2015-06-16 作为pi3k抑制剂的吡啶并[1,2-a]嘧啶酮类似物 Active CN106470992B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2014102712829 2014-06-17
CN201410271282.9A CN105461711B (zh) 2014-06-17 2014-06-17 作为PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物
CN201510324348 2015-06-12
CN2015103243480 2015-06-12
PCT/CN2015/081518 WO2015192760A1 (zh) 2014-06-17 2015-06-16 作为pi3k抑制剂的吡啶并［1，2-a］嘧啶酮类似物

Publications (2)

Publication Number Publication Date
CN106470992A CN106470992A (zh) 2017-03-01
CN106470992B true CN106470992B (zh) 2018-11-06

Family

ID=54934872

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580027396.1A Active CN106470992B (zh) 2014-06-17 2015-06-16 作为pi3k抑制剂的吡啶并[1,2-a]嘧啶酮类似物

Country Status (11)

Country Link
US (1) US9856256B2 (cg-RX-API-DMAC7.html)
EP (1) EP3159341B8 (cg-RX-API-DMAC7.html)
JP (1) JP6680774B2 (cg-RX-API-DMAC7.html)
KR (1) KR102495840B1 (cg-RX-API-DMAC7.html)
CN (1) CN106470992B (cg-RX-API-DMAC7.html)
AU (1) AU2015276699B2 (cg-RX-API-DMAC7.html)
CA (1) CA2951971C (cg-RX-API-DMAC7.html)
EA (1) EA032642B1 (cg-RX-API-DMAC7.html)
ES (1) ES2754264T3 (cg-RX-API-DMAC7.html)
TW (1) TWI628180B (cg-RX-API-DMAC7.html)
WO (1) WO2015192760A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108602815A (zh) * 2015-12-16 2018-09-28 正大天晴药业集团股份有限公司 吡啶并[1,2-a]嘧啶酮类似物、其晶型、其中间体及其制备方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110386932A (zh) 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
US12325695B2 (en) * 2019-01-24 2025-06-10 Jiangsu Aosaikang Pharmaceutical Co., Ltd. 5-(4-pyridyloxy)pyrazole compounds serving as TGF-βR1 kinase inhibitor
CA3162166A1 (en) 2019-12-02 2021-06-10 Storm Therapeutics Limited Polyheterocyclic compounds as mettl3 inhibitors
AU2021218925A1 (en) * 2020-02-10 2022-09-29 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Use of pyrido[1,2-a]pyrimidinone compound in treating lymphoma
WO2021180111A1 (zh) 2020-03-10 2021-09-16 正大天晴药业集团股份有限公司 包括吡啶并[1,2-a]嘧啶酮化合物的药物组合
US20230321104A1 (en) * 2020-09-15 2023-10-12 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Use of pyrido[1,2-a]pyrimidinone compound in treating peripheral t cell lymphoma
WO2022121929A1 (zh) * 2020-12-08 2022-06-16 正大天晴药业集团股份有限公司 吡啶并[1,2-a]嘧啶酮化合物的治疗妇科肿瘤的用途
WO2023169488A1 (zh) * 2022-03-09 2023-09-14 正大天晴药业集团股份有限公司 包括吡啶并[1,2-a]嘧啶酮化合物和EGFR抑制剂的药物组合

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103224496A (zh) * 2011-11-17 2013-07-31 山东轩竹医药科技有限公司 三环类PI3K和/或mTOR抑制剂
CN103539777A (zh) * 2012-07-13 2014-01-29 广东东阳光药业有限公司 Pi3激酶调节剂及其使用方法和用途
WO2014022128A1 (en) * 2012-07-29 2014-02-06 Calitor Sciences, Llc Pi3 kinase modulators and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0415185A (pt) * 2003-10-10 2006-11-28 Pfizer Prod Inc 2h-[1,2,4]triazol[4,3-a]pirazinas substituìdas como inibidores da gsk-3
CN101541783B (zh) * 2006-06-30 2014-10-01 苏尼西斯制药有限公司 吡啶酮基pdk1抑制剂
EP2211615A4 (en) * 2007-10-22 2010-10-13 Glaxosmithkline Llc PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS
WO2009155121A2 (en) * 2008-05-30 2009-12-23 Amgen Inc. Inhibitors of pi3 kinase
BR112012033402A2 (pt) * 2010-07-02 2017-01-24 Gilead Sciences Inc moduladores de canais de íons conforme os compostos heterocíclicos fundidos
WO2012037108A1 (en) * 2010-09-13 2012-03-22 Glaxosmithkline Llc Aminoquinoline derivatives as antiviral agents
TW201443037A (zh) * 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
BR112016029825B1 (pt) * 2014-06-17 2020-10-27 Cisen Pharmaceutical Co., Ltd. composto

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103224496A (zh) * 2011-11-17 2013-07-31 山东轩竹医药科技有限公司 三环类PI3K和/或mTOR抑制剂
CN103539777A (zh) * 2012-07-13 2014-01-29 广东东阳光药业有限公司 Pi3激酶调节剂及其使用方法和用途
WO2014022128A1 (en) * 2012-07-29 2014-02-06 Calitor Sciences, Llc Pi3 kinase modulators and methods of use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108602815A (zh) * 2015-12-16 2018-09-28 正大天晴药业集团股份有限公司 吡啶并[1,2-a]嘧啶酮类似物、其晶型、其中间体及其制备方法

Also Published As

Publication number Publication date
EP3159341A4 (en) 2018-05-16
US20170137420A1 (en) 2017-05-18
KR20170016465A (ko) 2017-02-13
JP6680774B2 (ja) 2020-04-15
WO2015192760A1 (zh) 2015-12-23
AU2015276699B2 (en) 2019-10-10
EA032642B1 (ru) 2019-06-28
EP3159341B8 (en) 2020-01-08
EP3159341B1 (en) 2019-08-21
EA201790016A1 (ru) 2017-06-30
KR102495840B1 (ko) 2023-02-03
EP3159341A1 (en) 2017-04-26
TW201625612A (zh) 2016-07-16
AU2015276699A1 (en) 2017-01-19
CA2951971A1 (en) 2015-12-23
JP2017519821A (ja) 2017-07-20
TWI628180B (zh) 2018-07-01
US9856256B2 (en) 2018-01-02
CN106470992A (zh) 2017-03-01
CA2951971C (en) 2024-09-10
ES2754264T3 (es) 2020-04-16

Similar Documents

Publication Publication Date Title
CN106470992B (zh) 作为pi3k抑制剂的吡啶并[1,2-a]嘧啶酮类似物
US10093656B2 (en) Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitor
CN105461711B (zh) 作为PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物
TWI600655B (zh) 作為ｍＴＯＲ／ＰＩ３Ｋ抑制劑的吡啶并［１，２－ａ］嘧啶酮類似物
CN110446712A (zh) 作为A2A受体抑制剂的[1,2,4]三唑并[1,5-c]嘧啶衍生物
ES2787449T3 (es) Compuesto de alfa y beta-amida insaturada derivado de benzotriazol usado como inhibidor de TGF-betaRI
CN105461712B (zh) 作为mTOR/PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物
US20180179209A1 (en) Jak inhibitors
WO2019134661A1 (zh) 异吲哚啉酮及其衍生物作为csf-1r抑制剂
US10654868B2 (en) Dihydropyrazole azepine compound serving as Akt inhibitor
TWI687420B (zh) 稠環或三環芳基嘧啶化合物用作激酶抑制劑
HK1238629B (zh) 作为pi3k抑制剂的吡啶并[1，2-a]嘧啶酮类似物
TWI690529B (zh) 羥基嘌呤類化合物及其應用
HK1238629A1 (en) Pyridino[1,2-a]pyrimidone analogue used as pi3k inhibitor
HK40000494A (en) BENZOTRIAZOLE-DERIVED α AND β UNSATURATED AMIDE COMPOUND USED AS TGF-βR1 INHIBITOR
HK40000494B (en) BENZOTRIAZOLE-DERIVED α AND β UNSATURATED AMIDE COMPOUND USED AS TGF-βR1 INHIBITOR

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1238629

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CP02 Change in the address of a patent holder
CP02 Change in the address of a patent holder

Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Patentee after: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Address before: 222062 Yuzhou South Road, Haizhou District, Lianyungang, Jiangsu 369

Patentee before: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.